AMLX Stock Recent News
AMLX LATEST HEADLINES
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Margaret Olinger - Chief Commercial Officer James Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Michael DiFiore - Evercore Inc. Marc Goodman - SVB Securities Neena Bitritto-Garg - Citigroup Inc. Ananda Ghosh - H.C. Wainwright & Co. Operator Good afternoon.
Yahoo Finance Live's Seana Smith looks at several stocks trending in the after-hours trading session.
Relvyrio, Amylyx's drug to treat ALS, a neurological disorder without a cure, was approved even though the treatment is very expensive.
After a long road, Amylyx Pharmaceuticals won FDA approval for its ALS treatment late Thursday, leading AMLX stock to surge. The post IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle appeared first on Investor's Business Daily.
The drug is the first that the Food and Drug Administration has approved for ALS, also known as Lou Gehrig's disease, in five years.
WASHINGTON — A much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.
This down market is giving us some really intriguing stocks at cheap prices.
Amylyx Pharmaceuticals has just one drug in its pipeline -- but it's for ALS, and the available treatments for that disease leave much to be desired.
The FDA will most likely approve this company's first drug, but what comes next is more difficult to predict.
The FDA's PCNSDAC recommends granting marketing approval to Amylyx's (AMLX) oral drug, which slows the progression of ALS.